凯普生物1月6日获融资买入253.78万元，融资余额8870.80万元

Group 1 - The core viewpoint of the news is that 凯普生物 (Capbio) is experiencing a decline in stock performance and financial metrics, with significant changes in financing and shareholder structure [1][2][3] Group 2 - On January 6, 凯普生物's stock fell by 0.35%, with a trading volume of 49.52 million yuan. The financing buy amount was 2.54 million yuan, while the financing repayment was 6.87 million yuan, resulting in a net financing outflow of 4.33 million yuan [1] - As of January 6, the total balance of margin trading for 凯普生物 was 88.75 million yuan, with a financing balance of 88.71 million yuan, accounting for 2.43% of the circulating market value, which is below the 10% percentile level over the past year [1] - In terms of securities lending, on January 6, 凯普生物 repaid 600 shares and sold 1,400 shares, with a selling amount of 7,910 yuan. The remaining securities lending volume was 7,400 shares, with a balance of 41,800 yuan, also below the 50% percentile level over the past year [1] Group 3 - As of December 20, the number of shareholders for 凯普生物 was 27,400, a decrease of 0.58% from the previous period, while the average circulating shares per person increased by 0.58% to 23,172 shares [2] - For the period from January to September 2025, 凯普生物 reported operating revenue of 486 million yuan, a year-on-year decrease of 20.38%, and a net profit attributable to shareholders of -128 million yuan, reflecting a year-on-year increase of 51.25% [2] Group 4 - Since its A-share listing, 凯普生物 has distributed a total of 485 million yuan in dividends, with 193 million yuan distributed over the past three years [3] - As of September 30, 2025, the top ten circulating shareholders of 凯普生物 included a new shareholder, the Medical Device ETF (159883), holding 2.39 million shares [3]